Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethoxanate is a small molecule drug of the phenothiazine class used as a cough suppressant. It was introduced in several European countries in the early to mid-20th century and marketed under various brand names. Its primary mechanism of action is believed to involve binding to the sigma-1 receptor in the brain (IC50 = 41 nM), which may contribute to its antitussive effects. In addition to suppressing cough, dimethoxanate may have analgesic, local anesthetic, and central nervous system depressant properties but can also cause side effects such as nausea and vomiting. The drug was withdrawn from the US market by the FDA in 1975 due to insufficient evidence of efficacy[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethoxanate.